• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

吡咯替尼对 HER2 阳性食管癌的放射增敏作用。

Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.

机构信息

Cancer Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.

Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, Hebei 067000, China.

出版信息

Biosci Rep. 2020 Feb 28;40(2). doi: 10.1042/BSR20194167.

DOI:10.1042/BSR20194167
PMID:32022229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7029153/
Abstract

Radiation therapy is a widely used treatment for esophageal cancer. However, radiation resistance might result in a poor prognosis. Overexpression of HER2 has been related to adaptive radiation resistance. Pyrotinib is a HER2 inhibitor that shows an anti-tumor effect in breast cancer. The present study aims to explore the influence of pyrotinib combined with radiotherapy on HER2-positive esophageal cancer cells and explore the underlying mechanism. We screened two cell lines (TE-1 and KYSE30) that highly express HER2 from several human esophageal cancer cell lines. Cells were treated with pyrotinib or/and radiation. Cell proliferation, cell cycle distribution, and cell migration were measured. The protein levels involved in cell cycle and DNA repair were measured by Western blot. Results showed that pyrotinib inhibited HER2 activation and exerted an anti-proliferative effect in TE-1 and KYSE30 cells. Furthermore, it enhanced the anti-proliferative effect of radiation in these two cell lines. These effects might be via inhibiting HER2 phosphorylation, inducing G0/G1 arrest, and reducing EMT and DNA repair. Our results indicated that pyrotinib sensitivitied HER2 positive esophageal cancer cells to radiation treatment through various mechanisms. These findings may provide a new therapeutic strategy for treating HER2 positive esophageal cancer.

摘要

放射疗法是治疗食管癌的常用方法。然而,放射抵抗可能导致预后不良。HER2 的过表达与适应性放射抵抗有关。吡咯替尼是一种 HER2 抑制剂,在乳腺癌中显示出抗肿瘤作用。本研究旨在探讨吡咯替尼联合放射治疗对 HER2 阳性食管癌细胞的影响,并探讨其潜在机制。我们从几种人食管癌细胞系中筛选出两种高表达 HER2 的细胞系(TE-1 和 KYSE30)。用吡咯替尼或/和放射处理细胞。测量细胞增殖、细胞周期分布和细胞迁移。通过 Western blot 测量参与细胞周期和 DNA 修复的蛋白水平。结果表明,吡咯替尼抑制 HER2 激活,并在 TE-1 和 KYSE30 细胞中发挥抗增殖作用。此外,它增强了这两种细胞系中放射的抗增殖作用。这些作用可能是通过抑制 HER2 磷酸化、诱导 G0/G1 期阻滞以及减少 EMT 和 DNA 修复来实现的。我们的结果表明,吡咯替尼通过多种机制使 HER2 阳性食管癌细胞对放射治疗敏感。这些发现可能为治疗 HER2 阳性食管癌提供新的治疗策略。

相似文献

1
Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.吡咯替尼对 HER2 阳性食管癌的放射增敏作用。
Biosci Rep. 2020 Feb 28;40(2). doi: 10.1042/BSR20194167.
2
Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.吡咯替尼增强 HER2 过表达的胃癌和乳腺癌细胞的放射敏感性。
Oncol Rep. 2020 Dec;44(6):2634-2644. doi: 10.3892/or.2020.7820. Epub 2020 Oct 21.
3
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.CDK4/6 抑制剂哌柏西利增强吡咯替尼治疗 HER2 阳性乳腺癌的疗效。
Cancer Lett. 2019 Apr 10;447:130-140. doi: 10.1016/j.canlet.2019.01.005. Epub 2019 Jan 21.
4
Pyrotinib shows a potent antitumor effect on HER2-positive esophageal cancer cells by promoting HER2 proteasomal degradation.吡咯替尼通过促进 HER2 蛋白酶体降解,对 HER2 阳性食管癌细胞表现出强大的抗肿瘤作用。
Cell Mol Biol (Noisy-le-grand). 2023 Dec 20;69(14):191-196. doi: 10.14715/cmb/2023.69.14.31.
5
Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2 Breast Cancer Cells to 5-Fluorouracil.吡咯替尼增敏 5-氟尿嘧啶耐药 HER2 阳性乳腺癌细胞对 5-氟尿嘧啶的敏感性。
Oncol Res. 2020 Dec 10;28(5):519-531. doi: 10.3727/096504020X15960154585410. Epub 2020 Jul 29.
6
Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.阿帕替尼与吡咯替尼联合应用对 HER2 阳性胃癌具有协同作用,并通过干细胞因子/ c-kit 信号通路及其下游通路逆转获得性吡咯替尼耐药。
Gastric Cancer. 2021 Mar;24(2):352-367. doi: 10.1007/s10120-020-01126-9. Epub 2020 Oct 8.
7
Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells.细胞周期蛋白D1的抑制增强了食管癌细胞对放疗的敏感性并逆转上皮-间质转化。
Tumour Biol. 2016 Apr;37(4):5355-63. doi: 10.1007/s13277-015-4393-z. Epub 2015 Nov 11.
8
Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.吡咯替尼治疗增强 HER2 阳性脑转移乳腺癌患者的放射敏感性。
Anticancer Drugs. 2022 Jan 1;33(1):e622-e627. doi: 10.1097/CAD.0000000000001199.
9
FH535 increases the radiosensitivity and reverses epithelial-to-mesenchymal transition of radioresistant esophageal cancer cell line KYSE-150R.FH535可提高放射敏感性,并逆转放射抗性食管癌细胞系KYSE-150R的上皮-间质转化。
J Transl Med. 2015 Mar 31;13:104. doi: 10.1186/s12967-015-0464-6.
10
oil emulsion improves the effect of radiotherapy on esophageal cancer cells by inhibiting cyclin D1-CDK4/6 axis.油乳剂通过抑制细胞周期蛋白 D1-CDK4/6 轴提高放疗对食管癌的疗效。
World J Gastroenterol. 2019 May 28;25(20):2463-2472. doi: 10.3748/wjg.v25.i20.2463.

引用本文的文献

1
Pyrotinib monotherapy for advanced HER2-positive esophageal adenocarcinoma with trastuzumab resistance and chemotherapy intolerance: a case report and literature review.吡咯替尼单药治疗对曲妥珠单抗耐药且不耐受化疗的晚期HER2阳性食管腺癌:病例报告及文献综述
Discov Oncol. 2025 Mar 17;16(1):335. doi: 10.1007/s12672-025-02049-6.
2
Case report: Pyrotinib and tegafur combined with radiotherapy achieved notable response in HER2-amplified rectal cancer with multiple metastases after multiline treatments.病例报告:吡咯替尼和替加氟联合放疗在多线治疗后对HER2扩增的多发转移直肠癌取得显著疗效。
Front Pharmacol. 2024 Aug 13;15:1431542. doi: 10.3389/fphar.2024.1431542. eCollection 2024.
3

本文引用的文献

1
β-Cryptoxanthin induced anti-proliferation and apoptosis by G0/G1 arrest and AMPK signal inactivation in gastric cancer.β-隐黄质通过 G0/G1 期阻滞和 AMPK 信号失活诱导胃癌细胞增殖和凋亡。
Eur J Pharmacol. 2019 Sep 15;859:172528. doi: 10.1016/j.ejphar.2019.172528. Epub 2019 Jul 6.
2
Pyrotinib treatment on HER2-positive gastric cancer cells promotes the released exosomes to enhance endothelial cell progression, which can be counteracted by apatinib.吡咯替尼对HER2阳性胃癌细胞的治疗促进释放的外泌体增强内皮细胞进展,这一作用可被阿帕替尼抵消。
Onco Targets Ther. 2019 Apr 11;12:2777-2787. doi: 10.2147/OTT.S194768. eCollection 2019.
3
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.
曲妥珠单抗联合放疗和抗 HER2 靶向治疗 HER2 阳性乳腺癌脑转移
Eur J Med Res. 2023 Jan 16;28(1):27. doi: 10.1186/s40001-022-00894-7.
4
Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study.信迪利单抗为基础的方案治疗晚期食管癌的真实世界疗效和安全性:一项单中心回顾性观察研究。
Biomed Res Int. 2022 Aug 5;2022:7331687. doi: 10.1155/2022/7331687. eCollection 2022.
5
Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.乳腺癌患者循环肿瘤细胞:干性、上皮-间质转化特征与DNA损伤反应之间的平衡行为
Cancers (Basel). 2022 Feb 16;14(4):997. doi: 10.3390/cancers14040997.
6
Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.病例报告:吡咯替尼治疗广泛人表皮生长因子受体2阳性乳腺癌皮肤转移的显著疗效:5例报告
Front Oncol. 2021 Dec 16;11:729212. doi: 10.3389/fonc.2021.729212. eCollection 2021.
7
Predicting response to immunotherapy plus chemotherapy in patients with esophageal squamous cell carcinoma using non-invasive Radiomic biomarkers.利用无创放射组学生物标志物预测食管鳞癌患者免疫联合化疗的反应。
BMC Cancer. 2021 Oct 30;21(1):1167. doi: 10.1186/s12885-021-08899-x.
8
Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults.伊曲康唑多次给药增加中国健康成年人吡咯替尼的血浆暴露。
Drug Des Devel Ther. 2021 Jun 10;15:2485-2493. doi: 10.2147/DDDT.S312310. eCollection 2021.
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
CDK4/6 抑制剂哌柏西利增强吡咯替尼治疗 HER2 阳性乳腺癌的疗效。
Cancer Lett. 2019 Apr 10;447:130-140. doi: 10.1016/j.canlet.2019.01.005. Epub 2019 Jan 21.
4
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.非小细胞肺癌中的 HER2 外显子 20 插入对不可逆的泛 HER 受体酪氨酸激酶抑制剂吡咯替尼敏感。
Ann Oncol. 2019 Mar 1;30(3):447-455. doi: 10.1093/annonc/mdy542.
5
Pyrotinib: First Global Approval.吡咯替尼:全球首次获批。
Drugs. 2018 Nov;78(16):1751-1755. doi: 10.1007/s40265-018-0997-0.
6
RACK1 promotes radiation resistance in esophageal cancer via regulating AKT pathway and Bcl-2 expression.RACK1通过调节AKT信号通路和Bcl-2表达促进食管癌的放射抗性。
Biochem Biophys Res Commun. 2017 Sep 23;491(3):622-628. doi: 10.1016/j.bbrc.2017.07.153. Epub 2017 Jul 29.
7
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.吡咯替尼的发现与研发:一种新型不可逆表皮生长因子受体/人表皮生长因子受体 2 双酪氨酸激酶抑制剂,具有良好的安全性,可用于治疗乳腺癌。
Eur J Pharm Sci. 2017 Dec 15;110:51-61. doi: 10.1016/j.ejps.2017.01.021. Epub 2017 Jan 21.
8
Radiosensitization of esophageal carcinoma cells by knockdown of RNF2 expression.通过敲低RNF2表达对食管癌细胞进行放射增敏
Int J Oncol. 2016 May;48(5):1985-96. doi: 10.3892/ijo.2016.3404. Epub 2016 Feb 19.
9
Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries.食管癌:东西方国家的风险因素、筛查及内镜治疗
World J Gastroenterol. 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933.
10
HER2 expression in gastric and oesophageal cancer: a meta-analytic review.HER2在胃癌和食管癌中的表达:一项荟萃分析综述。
J Gastrointest Oncol. 2015 Apr;6(2):143-54. doi: 10.3978/j.issn.2078-6891.2014.107.